Literature DB >> 25949868

Immune signature of tumor infiltrating immune cells in renal cancer.

Katharina Geissler1, Paolo Fornara2, Christine Lautenschläger3, Hans-Jürgen Holzhausen4, Barbara Seliger1, Dagmar Riemann1.   

Abstract

Tumor-associated immune cells have been discussed as an essential factor for the prediction of the outcome of tumor patients. Lymphocyte-specific genes are associated with a favorable prognosis in colorectal cancer but with poor survival in renal cell carcinoma (RCC). Flow cytometric analyses combined with immunohistochemistry were performed to study the phenotypic profiles of tumor infiltrating lymphocytes (TIL) and the frequency of T cells and macrophages in RCC lesions. Data were correlated with clinicopathological parameters and survival of patients. Comparing oncocytoma and clear cell (cc)RCC, T cell numbers as well as activation-associated T cell markers were higher in ccRCC, whereas the frequency of NK cells was higher in oncocytoma. An intratumoral increase of T cell numbers was found with higher tumor grades (G1:G2:G3/4 = 1:3:4). Tumor-associated macrophages slightly increased with dedifferentiation, although the macrophage-to-T cell ratio was highest in G1 tumor lesions. A high expression of CD57 was found in T cells of early tumor grades, whereas T cells in dedifferentiated RCC lesions expressed higher levels of CD69 and CTLA4. TIL composition did not differ between older (>70 y) and younger (<58 y) patients. Enhanced patients' survival was associated with a higher percentage of tumor infiltrating NK cells and Th1 markers, e.g. HLA-DR+ and CXCR3+ T cells, whereas a high number of T cells, especially with high CD69 expression correlated with a worse prognosis of patients. Our results suggest that immunomonitoring of RCC patients might represent a useful tool for the prediction of the outcome of RCC patients.

Entities:  

Keywords:  CD13; CD57; CD69; MDSC, myeloid-derived suppressor cells; MFI, mean fluorescence intensity; NK, natural killer cells; PE, phycoerythrine; RCC, renal cell carcinoma; TIL, tumor-infiltrating lymphocytes; flow cytometry; immunohistochemistry; immunophenotype; mAb, monoclonal antibody; oncocytoma; renal cell carcinoma; survival; tumor infiltrating lymphocytes (TIL); tumor-associated macrophages (TAM)

Year:  2015        PMID: 25949868      PMCID: PMC4368143          DOI: 10.4161/2162402X.2014.985082

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  40 in total

Review 1.  Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma.

Authors:  Augusto C Ochoa; Arnold H Zea; Claudia Hernandez; Paulo C Rodriguez
Journal:  Clin Cancer Res       Date:  2007-01-15       Impact factor: 12.531

Review 2.  CD57+ T lymphocytes and functional immune deficiency.

Authors:  Daniele Focosi; Marco Bestagno; Oscar Burrone; Mario Petrini
Journal:  J Leukoc Biol       Date:  2009-10-30       Impact factor: 4.962

3.  Cancer statistics, 1987.

Authors:  E Silverberg; J Lubera
Journal:  CA Cancer J Clin       Date:  1987 Jan-Feb       Impact factor: 508.702

4.  Renal oncocytoma. II. Lectin and immunohistochemical features indicating an origin from the collecting duct.

Authors:  M Ortmann; M Vierbuchen; R Fischer
Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol       Date:  1988

5.  Prognostic value of diametrically polarized tumor-associated macrophages in renal cell carcinoma.

Authors:  Le Xu; Yu Zhu; Lian Chen; Huimin An; Weijuan Zhang; Guomin Wang; Zongming Lin; Jiejie Xu
Journal:  Ann Surg Oncol       Date:  2014-03-11       Impact factor: 5.344

6.  L1CAM promotes enrichment of immunosuppressive T cells in human pancreatic cancer correlating with malignant progression.

Authors:  Evelin Grage-Griebenow; Elfi Jerg; Artur Gorys; Daniel Wicklein; Daniela Wesch; Sandra Freitag-Wolf; Lisa Goebel; Ilka Vogel; Thomas Becker; Michael Ebsen; Christoph Röcken; Peter Altevogt; Udo Schumacher; Heiner Schäfer; Susanne Sebens
Journal:  Mol Oncol       Date:  2014-04-02       Impact factor: 6.603

7.  CD69+ CD4+ CD25- T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-beta 1.

Authors:  Yanmei Han; Qiuli Guo; Minggang Zhang; Zhubo Chen; Xuetao Cao
Journal:  J Immunol       Date:  2009-01-01       Impact factor: 5.422

Review 8.  Immune suppression in renal cell carcinoma.

Authors:  Bernhard Frankenberger; Elfriede Noessner; Dolores J Schendel
Journal:  Semin Cancer Biol       Date:  2007-06-23       Impact factor: 15.707

Review 9.  The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures.

Authors:  Jérôme Galon; Helen K Angell; Davide Bedognetti; Francesco M Marincola
Journal:  Immunity       Date:  2013-07-25       Impact factor: 31.745

10.  Increased expression of activation markers in renal cell carcinoma infiltrating lymphocytes.

Authors:  M Shabtai; H Ye; Z Frischer; J Martin; W C Waltzer; K Malinowski
Journal:  J Urol       Date:  2002-11       Impact factor: 7.450

View more
  66 in total

1.  Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer.

Authors:  Laetitia Fend; Sylvie Rusakiewicz; Julien Adam; Bérangère Bastien; Anne Caignard; Meriem Messaoudene; Christina Iribarren; Isabelle Cremer; Aurélien Marabelle; Christophe Borg; Michaela Semeraro; Luc Barraud; Jean-Marc Limacher; Alexander Eggermont; Guido Kroemer; Laurence Zitvogel
Journal:  Oncoimmunology       Date:  2016-05-13       Impact factor: 8.110

Review 2.  Renal cell carcinoma.

Authors:  James J Hsieh; Mark P Purdue; Sabina Signoretti; Charles Swanton; Laurence Albiges; Manuela Schmidinger; Daniel Y Heng; James Larkin; Vincenzo Ficarra
Journal:  Nat Rev Dis Primers       Date:  2017-03-09       Impact factor: 52.329

Review 3.  Current Status and Future Directions of Immunotherapy in Renal Cell Carcinoma.

Authors:  Bryden Considine; Michael E Hurwitz
Journal:  Curr Oncol Rep       Date:  2019-03-08       Impact factor: 5.075

4.  Exhaustion-associated regulatory regions in CD8+ tumor-infiltrating T cells.

Authors:  Giuliana P Mognol; Roberto Spreafico; Victor Wong; James P Scott-Browne; Susan Togher; Alexander Hoffmann; Patrick G Hogan; Anjana Rao; Sara Trifari
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-10       Impact factor: 11.205

5.  Predictors of disease aggressiveness influence outcome from immunotherapy treatment in renal clear cell carcinoma.

Authors:  Yasmin Kamal; Chao Cheng; H Robert Frost; Christopher I Amos
Journal:  Oncoimmunology       Date:  2018-10-16       Impact factor: 8.110

Review 6.  Obesity and CD8 T cell metabolism: Implications for anti-tumor immunity and cancer immunotherapy outcomes.

Authors:  William J Turbitt; Claire Buchta Rosean; K Scott Weber; Lyse A Norian
Journal:  Immunol Rev       Date:  2020-03-10       Impact factor: 12.988

7.  Evaluation of programmed cell death protein 1 (PD-1) expression as a prognostic biomarker in patients with clear cell renal cell carcinoma.

Authors:  Kyu Seo Kim; Rishi R Sekar; Dattatraya Patil; Michelle A Dimarco; Haydn T Kissick; Mehmet A Bilen; Adeboye O Osunkoya; Viraj A Master
Journal:  Oncoimmunology       Date:  2018-01-10       Impact factor: 8.110

8.  Patterns of immune infiltration in lung adenocarcinoma revealed a prognosis-associated microRNA-mast cells network.

Authors:  Chunlin Wang; Xi Tang; Jiaojian Wang; Yanhua Xu
Journal:  Hum Cell       Date:  2019-12-20       Impact factor: 4.174

9.  Nestin expression on tumour vessels and tumour-infiltrating macrophages define a poor prognosis subgroup of pt1 clear cell renal cell carcinoma.

Authors:  Jérôme Cros; Emilie Sbidian; Katia Posseme; Alexia Letierce; Catherine Guettier; Gérard Benoît; Sophie Ferlicot
Journal:  Virchows Arch       Date:  2016-06-17       Impact factor: 4.064

Review 10.  Expression and function of immune ligand-receptor pairs in NK cells and cancer stem cells: therapeutic implications.

Authors:  Ioannis A Voutsadakis
Journal:  Cell Oncol (Dordr)       Date:  2018-02-22       Impact factor: 6.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.